Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 30:3:100102.
doi: 10.1016/j.crphar.2022.100102. eCollection 2022.

Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state

Amit A Joharapurkar  1 , Vishal J Patel  1 , Samadhan G Kshirsagar  1 , Maulik S Patel  1 , Hardikkumar H Savsani  1 , Chetan Kajavadara  1 , Darshan Valani  1 , Mukul R Jain  1
Affiliations

Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state

Amit A Joharapurkar et al. Curr Res Pharmacol Drug Discov. .

Abstract

Many anemic chronic kidney disease (CKD) patients are refractory to erythropoietin (EPO) effects due to inflammation, deranged iron utilization, and generation of EPO antibodies. This work assessed the effect of desidustat, an inhibitor of hypoxia inducible factor (HIF) prolyl hydroxylase (PHD), on EPO-refractory renal anemia. Sprague Dawley rats were made anemic by cisplatin (5 ​mg/kg, IP, single dose) and turpentine oil (5 ​mL/kg, SC, once a week). These rats were given recombinant human EPO (rhEPO, 1 ​μg/kg) and desidustat (15 or 30 ​mg/kg) for eight weeks. Separately, rhEPO (1-5 ​μg/kg) was given to anemic rats to sustain the normal hemoglobin levels and desidustat (15 ​mg/kg) for eight weeks. In another experiment, the anemic rats were treated rhEPO (5 ​μg/kg) for two weeks and then desidustat (15 ​mg/kg) for the next two weeks. Dosing of rhEPO was thrice a week, and for desidustat, it was on alternate days. Desidustat inhibited EPO-resistance caused by rhEPO treatment, decreased hepcidin, IL-6, IL-1β, and increased iron and liver ferroportin. Desidustat reduced EPO requirement and anti-EPO antibodies. Desidustat also maintained normal hemoglobin levels after cessation of rhEPO treatment. Thus, novel prolyl hydroxylase inhibitor desidustat can treat EPO resistance via improved iron utilization and decreased inflammation.

Keywords: Antibody; Desidustat; EPO resistance; Inflammation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Figures

Image 1
Graphical abstract
Fig. 1
Fig. 1
Effect of desidustat on development of EPO-resistance in anemia induced by cisplatin and turpentine oil in rats. A, hemoglobin response over time, B, serum iron, C, liver iron, D, spleen iron, E, serum hepcidin, F, hepcidin expression in liver, G, ferroportin (FPN1) expression in liver, H, serum IL-6, I, serum IL-1β. The serum and tissue parameters (B to H) were measured at the end of 8 weeks treatment. The data expressed as mean ​± ​SEM, n ​= ​9 per group. ∗ indicate P ​< ​0.05 compared with vehicle control, $ indicate P ​< ​0.05 compared with rhEPO treatment.
Fig. 2
Fig. 2
Effect of desidustat on bone marrow histology on development of EPO-resistance in anemia induced by cisplatin and turpentine oil in rats. A, repsentative image Myeloid: Erythroid and Lymphoid: Erythroid cells ratio, The data expressed as mean ​± ​SEM, n ​= ​9 per group. B, representative images of the bone marrow cell population at the end of the treatment period. ∗ indicate P ​< ​0.05 compared with vehicle control, $ indicate P ​< ​0.05 compared with rhEPO treatment.
Fig. 3
Fig. 3
Desidustat protected against EPO refractory state in anemia induced by cisplatin and turpentine oil in rats. A, hemoglobin response over time, B, cumulative rhEPO dose given over time, C, antibody titer, and D, Serum EPO, at the end of 8 weeks of rhEPO and desidustat treatment. The data expressed as mean ​± ​SEM, n ​= ​9 per group. ∗ indicates P ​< ​0.05 compared with vehicle control, $ indicates P ​< ​0.05 compared with rhEPO treatment.
Fig. 4
Fig. 4
Effect of desidustat on hemoglobin after switching from rhEPO therapy in anemia induced by cisplatin and turpentine oil in rats. A, hemoglobin response over time, B, serum iron, C, liver iron, and D, spleen iron. Iron levels in serum, spleen and liver was measured at the end of experiment. The data expressed as mean ​± ​SEM, n ​= ​9 per group. ∗ indicates P ​< ​0.05 compared with vehicle control, $ indicates P ​< ​0.05 compared with rhEPO treatment.
See this image and copyright information in PMC

References

    1. Alves M.T., Vilaça S.S., Carvalho Md, Fernandes A.P., Dusse L.M., Gomes K.B. Resistance of dialyzed patients to erythropoietin. Rev. Bras. Hematol. Hemoter. 2015;37(3):190–197. - PMC - PubMed
    1. Ashby D.R., Gale D.P., Busbridge M., Murphy K.G., Duncan N.D., Cairns T.D., Taube D.H., Bloom S.R., Tam F.W., Chapman R., Maxwell P.H., Choi P. Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica. 2010;95(3):505–508. - PMC - PubMed
    1. Babitt J.L., Lin H.Y. Mechanisms of anemia in CKD. J. Am. Soc. Nephrol. 2012;23(10):1631–1634. - PMC - PubMed
    1. Bartels K., Grenz A., Eltzschig H.K. Hypoxia and inflammation are two sides of the same coin. Proc. Natl. Acad. Sci. U.S.A. 2013;110(46):18351–18352. - PMC - PubMed
    1. Beck J., Henschel C., Chou J., Lin A., Del Balzo U. Evaluation of the carcinogenic potential of roxadustat (FG-4592), a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase in CD-1 mice and Sprague Dawley rats. Int. J. Toxicol. 2017;36(6):427–439. - PubMed